CURE 📈 Direxion Daily Healthcare - Overview
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US25459Y8764 • Trading--Leveraged Equity
CURE: Pharmaceuticals, Biotechnology, Medical Equipment, Healthcare Providers
The fund invests at least 80% of its net assets in financial instruments, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index includes domestic companies from the healthcare sector, which includes: pharmaceuticals; health care equipment and supplies; health care providers and services; biotechnology; life sciences tools and services; and etc. It is non-diversified. ‣ Company URL: http://www.direxionfunds.com ‣ Domicile: United States
Additional Sources for CURE ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CURE ETF Overview
| Market Cap in USD | 175m |
| Category | Trading--Leveraged Equity |
| TER | 0.96% |
| IPO / Inception | 2011-06-15 |
CURE ETF Ratings
| Growth 5y | 32.6% |
| Fundamental | - |
| Dividend | 41.4% |
| Rel. Strength Industry | -105 |
| Analysts | - |
| Fair Price Momentum | 74.41 USD |
| Fair Price DCF | - |
CURE Dividends
| Dividend Yield 12m | 1.04% |
| Yield on Cost 5y | 1.33% |
| Annual Growth 5y | 47.78% |
| Payout Consistency | 39.5% |
CURE Growth Ratios
| Growth Correlation 3m | -93.6% |
| Growth Correlation 12m | 24.9% |
| Growth Correlation 5y | 62.9% |
| CAGR 5y | 5.03% |
| CAGR/Mean DD 5y | 0.24 |
| Sharpe Ratio 12m | -0.16 |
| Alpha | -59.23 |
| Beta | 2.27 |
| Volatility | 43.23% |
| Current Volume | 81.2k |
| Average Volume 20d | 55k |
What is the price of CURE stocks?
As of December 22, 2024, the stock is trading at USD 92.30 with a total of 81,237 shares traded.
Over the past week, the price has changed by -6.65%, over one month by -11.40%, over three months by -31.99% and over the past year by -1.33%.
As of December 22, 2024, the stock is trading at USD 92.30 with a total of 81,237 shares traded.
Over the past week, the price has changed by -6.65%, over one month by -11.40%, over three months by -31.99% and over the past year by -1.33%.
Is Direxion Daily Healthcare a good stock to buy?
Neither. Based on ValueRay Analyses, Direxion Daily Healthcare is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 32.57 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CURE as of December 2024 is 74.41. This means that CURE is currently overvalued and has a potential downside of -19.38%.
Neither. Based on ValueRay Analyses, Direxion Daily Healthcare is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 32.57 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CURE as of December 2024 is 74.41. This means that CURE is currently overvalued and has a potential downside of -19.38%.
Is CURE a buy, sell or hold?
Direxion Daily Healthcare has no consensus analysts rating.
Direxion Daily Healthcare has no consensus analysts rating.
What are the forecast for CURE stock price target?
According to ValueRays Forecast Model, CURE Direxion Daily Healthcare will be worth about 86.1 in December 2025. The stock is currently trading at 92.30. This means that the stock has a potential downside of -6.75%.
According to ValueRays Forecast Model, CURE Direxion Daily Healthcare will be worth about 86.1 in December 2025. The stock is currently trading at 92.30. This means that the stock has a potential downside of -6.75%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 86.1 | -6.7% |